Flerie
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
NET ASSET VALUE – 31 October 2024
MARKN.
On the 31 October 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,377 million and NAV per share was SEK 56.06.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Prokarium | 42% | 488 | 6.25 | 11.1% |
| Xspray Pharma | 18% | 351 | 4.50 | 8.0% |
| Empros Pharma | 79% | 204 | 2.62 | 4.7% |
| KAHR Medical | 31% | 202 | 2.59 | 4.6% |
| Atrogi | 37% | 176 | 2.25 | 4.0% |
| Lipum | 57% | 173 | 2.22 | 4.0% |
| Xintela | 56% | 143 | 1.84 | 3.3% |
| Microbiotica | 11% | 139 | 1.78 | 3.2% |
| Mendus | 24% | 123 | 1.57 | 2.8% |
| Geneos Therapeutics | 12% | 103 | 1.31 | 2.3% |
| Toleranzia | 66% | 90 | 1.15 | 2.1% |
| EpiEndo Pharmaceuticals | 9% | 58 | 0.74 | 1.3% |
| Synerkine Pharma | 43% | 53 | 0.68 | 1.2% |
| AnaCardio | 19% | 52 | 0.66 | 1.2% |
| Egetis Therapeutics | 2% | 31 | 0.40 | 0.7% |
| Buzzard Pharmaceuticals | 14% | 29 | 0.37 | 0.7% |
| Vitara Biomedical | 8% | 29 | 0.37 | 0.7% |
| Sixera Pharma | 23% | 26 | 0.33 | 0.6% |
| Alder Therapeutics | 21% | 17 | 0.22 | 0.4% |
| Amarna Therapeutics | 58% | 12 | 0.15 | 0.3% |
| Strike Pharma | 16% | 9 | 0.11 | 0.2% |
| Total | 2,507 | 32.11 | 57.3% | |
| Commercial Growth | ||||
| NorthX Biologics | 92% | 189 | 2.42 | 4.3% |
| Symcel | 31% | 169 | 2.16 | 3.9% |
| Provell Pharmaceuticals | 72% | 75 | 0.96 | 1.7% |
| Chromafora | 31% | 73 | 0.93 | 1.7% |
| Nanologica | 38% | 71 | 0.91 | 1.6% |
| A3P Biomedical | 8% | 42 | 0.54 | 1.0% |
| Frontier Biosolutions | 2% | 19 | 0.25 | 0.4% |
| Bohus Biotech | 45% | 17 | 0.21 | 0.4% |
| Total | 654 | 8.38 | 14.9% | |
| Limited Partnerships, total | 94 | 1.21 | 2.2% | |
| Assets related to Portfolio companies | 316 | 4.05 | 7.2% | |
| Other assets and liabilities | 805 | 10.31 | 18.4% | |
| Net asset value | 4,377 | 56.06 | 100.0% | |
* indirect shares in Provell Pharmaceuticals
| Datum | 2024-11-04, kl 08:00 |
| Källa | MFN |